Related references
Note: Only part of the references are listed.Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Rhonda Bentley-Lewis et al.
AMERICAN HEART JOURNAL (2015)
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Karen Whalen et al.
CLINICAL THERAPEUTICS (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ele Ferrannini et al.
EUROPEAN HEART JOURNAL (2015)
Association of Cardiometabolic Multimorbidity With Mortality The Emerging Risk Factors Collaboration
Emanuele Di Angelantonio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Bernard Zinman et al.
CARDIOVASCULAR DIABETOLOGY (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Inhibiting Mitochondrial Na+/Ca2+ Exchange Prevents Sudden Death in a Guinea Pig Model of Heart Failure
Ting Liu et al.
CIRCULATION RESEARCH (2014)
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
S. Sha et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy
Kento Kitada et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2014)
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Alan Sinclair et al.
BMC ENDOCRINE DISORDERS (2014)
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael A. Nauck
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
Timo Rieg et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Late Sodium Current Inhibition in Acquired and Inherited Ventricular (dys)function and Arrhythmias
Carol Ann Remme et al.
CARDIOVASCULAR DRUGS AND THERAPY (2013)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of Dapagliflozin on Cardiovascular Risk Factors
Agata Ptaszynska et al.
POSTGRADUATE MEDICINE (2013)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar et al.
BMJ OPEN (2012)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Glucose Control by the Kidney: An Emerging Target in Diabetes
Olivera Marsenic
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
Sanjay K. Banerjee et al.
CARDIOVASCULAR RESEARCH (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods
John B. Buse
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Adaptation and maladaptation of the heart in diabetes: Part I General concepts
H Taegtmeyer et al.
CIRCULATION (2002)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
